BACKGROUND
Castration resistant prostate cancer (CRPC) is an incurable disease with limited therapeutic options and novel therapies are urgently needed. Prostate specific membrane antigen (PSMA) is a protein highly expressed on the surface of prostate cancer cells; expression increases with disease progression. Therapies targeted to PSMA, such as anti-PSMA radioligand conjugates, have shown promise in clinical trials, validating this target for CRPC. T-cell recruiting bispecific antibodies (T-BsAbs) have demonstrated potent tumor killing activity, but immune-mediated toxicity, especially cytokine release syndrome, have hampered T-cell redirecting therapies to date. Using Teneobio's unique antibody discovery platform, we have developed a fully human CD3xPSMA bispecific antibody (TNB-585) that retains the potent cytotoxicity but with significantly reduced cytokine release.
METHODS
Antibodies targeting CD3 and PSMA were generated via immunization of our proprietary transgenic animals (UniRat™, OmniFlic™) that are engineered to produce fully human antibodies. Candidate antibodies were selected by repertoire deep sequencing of B-cells from draining lymph nodes, followed by high-throughput gene assembly and recombinant expression. Bispecific antibodies targeting CD3 and PSMA were assembled and evaluated for their ability to selectively activate primary human T-cells and eliminate PSMA+ tumor cells in vitro and in vivo. T-cell activation surface markers, cytokine production and tumor cell cytotoxicity were measured.
RESULTS
Primary human T-cells were activated only in the presence of both TNB-585 and PSMA (either recombinant or cell-surface protein). Potent and selective cytotoxicity against PSMA-positive tumor cells was observed in co-cultures of primary human T-cells and tumor cells treated with TNB-585. Strikingly, TNB-585 mediated comparable tumor cell cytotoxicity to CD3xPSMA T-BsAbs containing a high affinity anti-CD3 domain, but with significantly reduced cytokine production. Preliminary In vivo xenograft experiments showed tumor growth inhibition in NOG mice.
CONCLUSIONS
We have created a novel CD3xPSMA T-BsAb that mediates T-cell killing of PSMA+ tumor cells with minimal production of cytokines. This molecule may improve safety, efficacy, and offer opportunities for combination therapy to treat CRPC.
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